Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $93.3 million.

  • Angiodynamics' Total Liabilities fell 1091.22% to $93.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $93.3 million, marking a year-over-year decrease of 1091.22%. This contributed to the annual value of $97.2 million for FY2025, which is 1330.33% down from last year.
  • Per Angiodynamics' latest filing, its Total Liabilities stood at $93.3 million for Q4 2025, which was down 1091.22% from $86.8 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' Total Liabilities ranged from a high of $154.3 million in Q2 2023 and a low of $66.1 million during Q3 2023
  • For the 5-year period, Angiodynamics' Total Liabilities averaged around $114.4 million, with its median value being $112.8 million (2022).
  • Its Total Liabilities has fluctuated over the past 5 years, first crashed by 5394.16% in 2023, then surged by 4671.71% in 2024.
  • Quarter analysis of 5 years shows Angiodynamics' Total Liabilities stood at $121.7 million in 2021, then rose by 23.42% to $150.2 million in 2022, then tumbled by 34.51% to $98.4 million in 2023, then increased by 6.49% to $104.8 million in 2024, then fell by 10.91% to $93.3 million in 2025.
  • Its last three reported values are $93.3 million in Q4 2025, $86.8 million for Q3 2025, and $97.2 million during Q2 2025.